Frontlight ResearchEarly access
Active, not recruitingNo phase
Evidence For Fusion In Spine With Orthoss®
Key facts
- Who runs it
- Geistlich Pharma AG
- Where
- Germany3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 65 people, planned
- Started
- 18 Jan 2019
- Expected to end
- Dec 2026
- Type of study
- Observational
- Treatments tested
- Orthoss
- Record updated
- 11 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- The patient (male or female) must be 18 years or older
- The patient must be a candidate diagnosed with either degenerative disc disease including 1-2 level (L4-L5 and/or L5-S1) or dysplasic spondylolisthesis (degree 1 or 2) or lumbar stenosis
- If the patient is of child-bearing potential, the patient confirms not to be pregnant
- The patient is able to comply with the clinical investigation-related procedures such as attending all follow-up procedures
- The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent including the use of the anonymized data for scientific publication
- The patient will not participate in another clinical investigation during this clinical investigation
Who cannot take part
- General contraindications for surgical treatment are present
- The patient is currently being treated with radiation, chemotherapy, immunosuppression or steroid therapy dose equivalent of more than 5mg prednisolon
- The patient has a medical history of alcohol or drug abuse within the last year prior to the screening examination
- The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years
- The patient has acute or chronic infection at the surgical site
- The patient has a known allergy to bovine bone material
- Women of childbearing age who are not using a highly effective method of birth control
- The patient is pregnant or nursing
- Vulnerable population
- Patient is currently participating, or has participated in another clinical investigation within 6 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the performance and safety of the Orthoss® as a bone graft extender in lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1).
The group in the trial
- Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)
All surgical procedures to be performed during this clinical trial are part of the routine procedures for lumbar spondylodesis by using transforaminal lumbar interbody fusion (TLIF) and posterior lumbar interbody fusion (PLIF) techniques in the 1-2 levels (L4-L5 and/or L5-S1). Patients will receive surgery according to standard procedures.
Treatment: Orthoss
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 11 September 2026